Alnylam in US$2.8bn biobucks deal with Roche
siRNA specialist Alnylam Pharmaceuticals Roche has received US$310m upfront from Swiss Roche AG for the ex-US commercialisation rights of zilebesiran, an new antihypertensive.
T
Resistance blocker of immune checkpoint inhibitors gets patented
The EPO has granted a patent to Domain Therapeutics Phase I candidate DT-9081 designed to reverse PGE2-mediated immunosuppression used by tumours to bypass the immune system.
Lilly presents impressing results for Alzheimer’s drug donanemab
Eli Lilly’s Alzheimer’s drug donanemab has speedy removed amyloid plaques in a pivotal Phase III trail halting disease progression for one year in half of patients.
Biomethane fuel offers negative carbon footprint
Although the EU Commission wants to abolish the internal combustion engine in individual transport through eMobility, biofuels are far from dead, according to a new study.
Carbios raises 141m to boost enzymatic PET recycling
In an oversubscribed capital increase, Carbios SAS has raised 141m, the largest on Euronext growth since 2015.
EG 427 expands Series A closing to 18m
Paris-based gene therapy vector specialist EG 427 SAS has closed a Series A financing at 18m raising additional 5m in the final closing.
Seed money for unique topical hair growth inducer
Mallia Therapeutics GmbH has raised seed money to accelerate preclinical research and start Phase I testing of a baldness cure with unique MOA named soluble CD83.
Evotec earns US$40m in global licence deal with BMS
German CRO Evotec SE enters licence agreement Bristol Myers Squibb within its neuroscience partnership providing US$40m upfront, milestones and double-digit sales royalities.
Nanobiotix SA licences NBTXR3 to J&J
Paris-based Nanobiotix SA has signed a potential US$1.8bn oncology deal with Janssen Pharmaceutica NV for the global commercialisation rights of its radioenhancer NBTXR3.
Living therapy: Microbial immunotherapy of Exeliom Biosciences gets a boost
Exeliom Biosciences, a French company focused on the microbiome-immunomodulation axis to develop next-generation immunotherapies, has announced the closing of its 24m (US$26m) Series A financing to advance the clinical development of its therapeutic pipeline, including several clinical trials of EXL01, a novel bacterial immunotherapy with applications in cancer and infectious diseases.